The antipoverty vaccines

Hotez, Peter J.; Ferris, Meghan T.

doi:10.1016/j.vaccine.2006.05.008

Cited by 158 publications

(133 citation statements)

References 108 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…New drugs and vaccines may be called for some of the high prevalence NTDs like hookworm infection, schistosomiasis, Chagas disease and leishmaniasis. Because of their potential for improving health & economic development, NTDs vaccines are sometimes referred to as antipoverty vaccines (37,38 …”

Section: Million+ 51mentioning

confidence: 99%

Neglected Tropical Diseases: Current Snapshot

Gupta¹,

Soni²,

Gupta³

2016

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Section: Million+ 51mentioning

confidence: 99%

Neglected Tropical Diseases: Current Snapshot

Gupta¹,

Soni²,

Gupta³

2016

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

“…However, among the poorest people living in the US, there is a group of serious parasitic and bacterial disease including toxocariasis, cysticercosis and Chagas disease. Toxocariasis is a disease belonging to the group known as the "neglected infections of poverty", because it is a disease that has been forgotten by the US public health community and it promotes poverty through its impact on child health and development [9,10].…”

Section: Toxocariasis In the United Statesmentioning

confidence: 99%

Toxocariasis in the Americas: Burden and Disease Control

et al. 2014

View full text Add to dashboard Cite

Human toxocariasis is a zoonotic parasitic disease that represents extensive morbidity in many countries. Caused by Toxocara canis and Toxocara cati, the clinical spectrum of this helminthiasis can be extended from asymptomatic forms up to life-threatening syndromes, such as the visceral larva migrans. Its epidemiology and burden is not clear; many times it is not diagnosed and, in most countries, it is not a notifiable disease. Some recent reviews have shown a large range of variability in terms of reported seroprevalence by countries. In this review, we summarized information regarding human toxocariasis burden of disease and control efforts in the region of the Americas.

show abstract

“…So far, however, it appears that poverty is linked to NTDs by virtue of their long-term negative effects on child intellect and cognition, the ability of adults to go to work, and maternal-child health especially around pregnancy, although there are probably other mechanisms as well. 5 , 7 , 10 Accordingly, interventions that can treat or prevent NTDs can be considered as potential effective antipoverty measures.…”

Section: Introduction: the Ntdsmentioning

confidence: 99%

“…The framework of antipoverty vaccines was shaped beginning in 2006, 10 in order to promote the concept of developing new vaccines for poverty-promoting NTDs. But progress in antipoverty vaccine development has been slow relative to scale-up for integrated MDA.…”

Section: Introduction: the Ntdsmentioning

confidence: 99%

The global fight to develop antipoverty vaccines in the anti-vaccine era

Hotez

2018

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Antipoverty vaccines are the vaccines targeting a group of approximately 20 neglected tropical diseases (NTDs), as currently defined by the World Health Organization (WHO). The “antipoverty” moniker refers to the fact that NTDs trap populations in poverty due to their chronic and deleterious effects on child intellect and worker productivity. Therefore, NTD vaccines can be expected to promote both global health and economic advancement. Unfortunately, antipoverty vaccine development has lagged behind vaccines for major childhood infections and pandemic threats, despite evidence for their cost-effectiveness and cost-savings. Currently, the only licensed vaccines for NTDs include those for yellow fever, dengue, and rabies, although several other NTD vaccines for hookworm disease, schistosomiasis, leishmaniasis, and Zika and Ebola virus infections are in different stages of clinical development, while others are at the preclinical development stage. With the exception of the viral NTD vaccines there so far has been minimal industry interest in the antipoverty vaccines, leaving their development to a handful of non-profit product development partnerships. The major scientific and geopolitical hurdles to antipoverty vaccine development are discussed, including a rising antivaccine (“antivax”) movement now entering highly populated low- and middle-income countries.

show abstract

The antipoverty vaccines

Cited by 158 publications

References 108 publications

Neglected Tropical Diseases: Current Snapshot

Neglected Tropical Diseases: Current Snapshot

Toxocariasis in the Americas: Burden and Disease Control

The global fight to develop antipoverty vaccines in the anti-vaccine era

Contact Info

Product

Resources

About